Result Test Name
QUEST KRAS MUTATION ANALYSIS
Laboratory
QUEST LAB
Result Test Code
123924770
Laboratory Test Name
QUEST KRAS MUTATION ANALYSIS
Reportable Test Name
-
Result LOINC
21702-6
Collection Container
PATH CONTAINER
Units
-
Collection Requirements
Preferred Specimen(s) Formalin-fixed paraffin-embedded tissue block Alternative Specimen(s) 5 mL whole blood collected in an EDTA (lavender-top) tube or sodium heparin (green-top) tube 3 mL bone marrow aspirate submitted in an EDTA (lavender-top) tube or sodium heparin (green-top) tube 8 unstained charged (+) slides Minimum Volume 3 mL whole blood 1 mL bone marrow aspirate 4 unstained charged (+) slides Collection Instructions Submission of formalin-fixed paraffin-embedded tissue is the preferred sample type. Other sample types listed are acceptable for testing. For submission of paraffin block another preferred specimen type tissue source and block ID are required on the requisition form. A pathology report must be submitted. Whole blood: Follow standard whole blood collection procedures. Collect 3-5 mL whole blood in an EDTA tube. Record sample type collection time and date onto tube and requisition form. Bone marrow collection: The notation of sample type collection time and date onto the tube and requisition form is required. Ship sample at refrigerated temperature or room temperature. Ship immediately to maintain stability. Do not reject specimens. Send to laboratory for screening.
Container Temp
Room Temperature (1)
Container Volume
1.000
Test Info
KRAS Mutation Analysis - Activating KRAS mutations can be found in human malignancies with an overall frequency of 15-20% including 25-35% of lung adenocarcinomas 60-90% of malignant tumors of the pancreas 30-45% of colorectal carcinomas and 18-30% of hematopoietic neoplasms of myeloid origin. KRAS proteins have been shown to influence proliferation differentiation transformation and apoptosis by relaying mitogenic and growth signals into the cytoplasm and the nucleus. Mutations leading to an amino acid substitution at positions 12 13 61 and 146 of KRAS are the most common in naturally occurring neoplasms. The presence of KRAS mutation in most tumor types is associated with adverse prognosis as well as resistance to receptor tyrosine kinase-directed targeted therapies including against EGFR. KRAS along with others is an emerging biomarkers in NSCLC (non-small cell lung cancer) and other tumor types. Currently in NSCLC the KRAS G12C mutation is prevalent in approximately 1*
Shipping Instructions
Transport Container Formalin-fixed paraffin-embedded tissue block Transport Temperature Room temperature Specimen Stability Formalin-fixed paraffin embedded tissue/slides Room temperature: 5 years Refrigerated: 5 years Frozen: Unacceptable Whole blood and bone marrow Room temperature: 72 hours Refrigerated: 72 hours Frozen: Unacceptable